Current treatments for non-small cell lung cancer

Guo, Qianqian; Liu, Liwei; Chen, Zelong; Fan, Yannan; Zhou, Yang; Yuan, Ziqiao; Zhang, Wenzhou

doi:10.3389/fonc.2022.945102

Cited by 34 publications

(35 citation statements)

References 188 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Previous abundant studies have attempted to seek combination therapies with chemotherapy for lung cancer treatment [18][19][20][21][22]. They found that cancer treatment efficacy was enhanced by the combination of chemotherapy drugs with targeted drugs, Chinese medicine drugs or plant compounds [19][20][21][22].…”

Section: Discussionmentioning

confidence: 99%

Combined time-restricted feeding and cisplatin enhance the anti-tumor effects in cisplatin-resistant and -sensitive lung cancer cells

Chen

Shi

et al. 2022

Med Oncol

View full text Add to dashboard Cite

Combination therapy as an important treatment option for lung cancer has been attracting attention due to the primary and acquired resistance of chemotherapeutic drugs in the clinical application. In the present study, as a new therapy strategy, concomitant treatment with time-restricted feeding (TRF) plus cisplatin (DDP) on lung cancer growth was investigated in DDP-resistant and DDP-sensitive lung cancer cells. We first found that TRF significantly enhanced the drug susceptibility of DDP in DDP-resistant A549 (A549/DDP) cell line, illustrated by reversing the inhibitory concentration 50 (IC50) values of A549/DDP cells to normal level of parental A549 cells. We also found that TRF markedly enhanced DDP inhibition on cell proliferation, migration, as well as promoted apoptosis compared to the DDP alone group in A549, H460 and A549/DDP cells lines. We further revealed that the synergistic anti-tumor effect of combined DDP and TRF was greater than that of combined DDP and simulated fasting condition (STS), a known anti-tumor cellular medium. Moreover, mRNA sequence analysis from A549/DDP cell line demonstrated the synergistic anti-tumor effect involved in upregulated pathways in p53 signaling pathway and apoptosis. Notably, compared with the DDP alone group, combination of TRF and DDP robustly upregulated the P53 protein expression without mRNA level change by regulating its stability via promoting protein synthesis and inhibiting degradation, revealed by cycloheximide and MG132 experiments. Collectively, our results suggested that TRF in combination with cisplatin might be an additional novel therapeutic strategy for patients with lung cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Combined time-restricted feeding and cisplatin enhance the anti-tumor effects in cisplatin-resistant and -sensitive lung cancer cells

Chen

Shi

et al. 2022

Med Oncol

View full text Add to dashboard Cite

show abstract

“…34 Notably, 5-FU is not listed among the list of current treatments for patients with NSCLC. 72 Although 5-FU is not currently used, our results demonstrate that the 5-FU modification is necessary for miR-129 to enter cells without the aid of a delivery vehicle. Because the inhibitory effect of 5-FU-miR-129 can be achieved under vehicle-free conditions, we believe that this feature can overcome a key obstacle of RNA-based therapeutics.…”

Section: Discussionmentioning

confidence: 75%

Development of a 5-FU Modified miR-129 Mimic as a Therapeutic for Non-Small Cell Lung Cancer

Hwang

Yuen

Fesler³

et al. 2022

Preprint

View full text Add to dashboard Cite

Lung cancer is the leading cause of cancer-related deaths in the United States with non-small cell lung cancer (NSCLC) accounting for most cases. Despite advances in cancer therapeutics, the 5-year survival rate has remained poor due to several contributing factors, including its resistance to therapeutics. Therefore, there is a pressing need to develop therapeutics that can overcome resistance. Non-coding RNAs, including microRNAs (miRNAs), have been found to contribute to cancer resistance and therapeutics by modulating the expression of several targets involving multiple key mechanisms. In this study, we investigated the therapeutic potential of miR-129 modified with 5-fluorouracil (5-FU) in NSCLC. Our results show that 5-FU modified miR-129 (5-FU-miR-129) inhibits proliferation, induces apoptosis, and retains function as a miRNA in NSCLC cell lines A549 and Calu-1. Notably, we observed that 5-FU-miR-129 was able to overcome resistance to tyrosine kinase inhibitors and chemotherapy in cell lines resistant to erlotinib or 5-FU. Furthermore, we observed that the inhibitory effect of 5-FU-miR-129 can also be achieved in NSCLC cells under vehicle-free conditions. Finally, 5-FU-miR-129 inhibited NSCLC tumor growth and extended survival in vivo without toxic side effects. Altogether, our results demonstrate the potential of 5-FU-miR-129 as a highly potent cancer therapeutic in NSCLC.

show abstract

“…One of the most common types of human cancer is non-small cell lung cancer (NSCLC) which is characterized by invasion, migration, rapid growth, and reoccurrence ( Guo et al, 2022 ). In vitro studies on NSCLC showed that treatment with calotropin promoted apoptosis by increasing the expression of pro-apoptosis genes: caspase-3, caspase-8 , and apoptotic protease activating factor-1 (Apaf-1) and downregulated expression of anti-apoptotic proteins: p53, B-cell lymphoma (Bcl 2) and Bclw ( Paesmans et al, 2015 ).…”

Section: Therapeutic Activity Cellular and Molecular Mechanisms Of Ca...mentioning

confidence: 99%

An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer

et al. 2023

View full text Add to dashboard Cite

Calotropin is a pharmacologically active compound isolated from milkweed plants like Calotropis procera, Calotropis gigantea, and Asclepias currasavica that belong to the Asclepiadaceae family. All of these plants are recognised as medical traditional plants used in Asian countries. Calotropin is identified as a highly potent cardenolide that has a similar chemical structure to cardiac glycosides (such as digoxin and digitoxin). During the last few years, cytotoxic and antitumor effects of cardenolides glycosides have been reported more frequently. Among cardenolides, calotropin is identified as the most promising agent. In this updated and comprehensive review, we aimed to analyze and discuss the specific mechanisms and molecular targets of calotropin in cancer treatment to open new perspectives for the adjuvant treatment of different types of cancer. The effects of calotropin on cancer have been extensively studied in preclinical pharmacological studies in vitro using cancer cell lines and in vivo in experimental animal models that have targeted antitumor mechanisms and anticancer signaling pathways. The analyzed information from the specialized literature was obtained from scientific databases until December 2022, mainly from PubMed/MedLine, Google Scholar, Scopus, Web of Science, and Science Direct databases using specific MeSH search terms. The results of our analysis demonstrate that calotropin can be a potential chemotherapeutic/chemopreventive adjunctive agent in cancer pharmacotherapeutic management.

show abstract

Current treatments for non-small cell lung cancer

Cited by 34 publications

References 188 publications

Combined time-restricted feeding and cisplatin enhance the anti-tumor effects in cisplatin-resistant and -sensitive lung cancer cells

Combined time-restricted feeding and cisplatin enhance the anti-tumor effects in cisplatin-resistant and -sensitive lung cancer cells

Development of a 5-FU Modified miR-129 Mimic as a Therapeutic for Non-Small Cell Lung Cancer

An updated pharmacological insight into calotropin as a potential therapeutic agent in cancer

Contact Info

Product

Resources

About